$KPRX Cashflow Statement | Understand Stock

$KPRX

$1.76 -$0.60 (25.42%) Close

$KPRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating Activities
Net (Loss) Income
Adjustments to Reconcile Net (Loss) Income to Net Cash (Used in) Provided by Operating Activities:
Closure of EyeGate Pharma S.A.S. Subsidiary
Depreciation and Amortization
Impairment of intangible assets
Reduction of Right-of-Use Assets
Stock-Based Compensation
Contingent Consideration
Expiration of Prepaid Agreement
Change in Fair Value of Contingent Consideration
Change in Fair Value of Warrant Liability
Accretion of Discount on Marketable Securities
Change in Accrued Interest on Marketable Securities
Net Realized Gain on Marketable Securities
Change in Unrealized Gain on Cash Equivalents
Deferred Taxes
Paycheck Protection Program Loan Forgiveness
Goodwill Impairment Loss
Intangible Asset Impairment Loss
Loss on Disposal of Assets
Changes in Operating Assets and Liabilities:
Prepaid Expenses and Other Current Assets
Collaboration Receivables
Tax and Other Receivables
Other Assets
Accounts Payable
Accrued Expenses
Accrued Collaboration Credit
Operating Lease Liabilities
Deferred Collaboration Revenue

Net Cash (Used in) Provided by Operating Activities
Investing Activities:
Proceeds on Sale of Equipment
Purchases of Property and Equipment
Acquisitions, Net of Cash Acquired
Dissolution of Foreign Entity
Purchases of Marketable Securities
Sales of Marketable Securities
Maturities of Marketable Securities
Net Cash Provided by (Used in) Investing Activities

Financing Activities:
Payments Made for Fractional Shares Related to the Reverse Stock Split
Repayment of Loan Payable
Issuance Costs for Private Placement
Public Offering
Equity Line Of Credit
Total issuance Costs for Private Placement
Exercise of Warrants
Paycheck Protection Program Loan Proceeds
Payment of Contingent Consideration
Proceeds from Line of Credit
Repayments of Line of Credit
Net Cash Provided by Financing Activities

Effect of Exchange Rate Changes on Cash
Net Increase in Cash and Cash Equivalents
Cash and Cash Equivalents, Including Restricted Cash, Beginning of Year
Cash and Cash Equivalents, Including Restricted Cash, End of Year
Supplemental Disclosures of Noncash Operating and Financing Activities:
Conversion of Series C Preferred Stock into Common Stock
Conversion of Series D Preferred Stock into Common Stock
Conversion of Series F Preferred Stock into Common Stock
Series C Preferred Stock
Series D Preferred Stock
Series E Preferred Stock
Series F Preferred Stock

Creation of Right-of-Use Assets and Related Lease Liabilities
Tenant Improvements Paid Directly by Lessor
Grant of Restricted Stock Awards

Comments